BMJ oncology · 2026
Investigating the determinants of immunotherapy response in the primary tumour of clear cell renal cell carcinoma (RCC).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tang Cerise, Poduval Deepak, Lee Suzanna, Panian Justine, Saidian Ava, Rout Rishabh, van Dijk David, McKay Rana R, Braun David A
Аннотация
OBJECTIVE: Immune checkpoint inhibitors (ICIs) have demonstrated durable clinical benefit in a subset of patients with metastatic renal cell carcinoma (RCC), yet the molecular features that govern therapeutic response within the primary tumour remain poorly defined. This is of particular importance in the current era, where cytoreductive nephrectomy is less commonly performed and many patients with metastatic disease still have the primary RCC tumour in place. To deepen our understanding of ICI response in the primary tumour and to understand the evolution of RCC on ICI, we conducted a comprehensive genomic analysis of paired pretreatment and post-treatment primary RCC tumours treated with ICI.
DESIGN SETTING AND PARTICIPANTS: We performed a multimodal analysis of 46 ICI-treated primary RCC tumour specimens from 33 patients, including 13 matched pretreatment biopsies and post-treatment nephrectomies to investigate the genomic and transcriptomic evolution of tumours exposed to ICI therapy. Seventeen samples were from responders (>30% radiographic shrinkage, n=4 pretreatment, n=13 post-treatment) and 29 samples were from non-responders (<30% shrinkage, n=11 pretreatment, n=18 post-treatment). Whole-exome and RNA-seq were performed at Caris Life Sciences.
RESULTS: In this limited cohort, pretreatment responder biopsies are enriched for immune-related gene programmes, including B cell and tertiary lymphoid structure signatures. Longitudinal analysis reveals immune pathways decline in responders while non-responders show signatures of T cell exhaustion. However, the small number of patients with paired samples constrains statistical power and limits generalisability.
CONCLUSIONS: Our findings highlight the value of primary tumour profiling in understanding ICI response dynamics in RCC.
DESIGN SETTING AND PARTICIPANTS: We performed a multimodal analysis of 46 ICI-treated primary RCC tumour specimens from 33 patients, including 13 matched pretreatment biopsies and post-treatment nephrectomies to investigate the genomic and transcriptomic evolution of tumours exposed to ICI therapy. Seventeen samples were from responders (>30% radiographic shrinkage, n=4 pretreatment, n=13 post-treatment) and 29 samples were from non-responders (<30% shrinkage, n=11 pretreatment, n=18 post-treatment). Whole-exome and RNA-seq were performed at Caris Life Sciences.
RESULTS: In this limited cohort, pretreatment responder biopsies are enriched for immune-related gene programmes, including B cell and tertiary lymphoid structure signatures. Longitudinal analysis reveals immune pathways decline in responders while non-responders show signatures of T cell exhaustion. However, the small number of patients with paired samples constrains statistical power and limits generalisability.
CONCLUSIONS: Our findings highlight the value of primary tumour profiling in understanding ICI response dynamics in RCC.